HRA Pharma has entered into an exclusive agreement with the Australian drug delivery company Acrux to market and distribute Acrux’s transdermal estradiol spray in France, Germany, the UK, Italy, Spain, Greece, Turkey and Cyprus. The product will complement HRA Pharma’s existing portfolio of products addressing reproductive health as well as its growing operational presence in Europe.
Under the terms of the agreement, HRA Pharma will be responsible for obtaining marketing approval for Acrux’s transdermal estradiol spray in France, Germany, the UK, Spain, Italy, Greece, Turkey and Cyprus through a Mutual Recognition Procedure.
The small, hand-held spray, designed to provide an easy and convenient means to deliver a preset dose of estradiol via the skin in order to reduce symptoms of menopause, is marketed under the brand name Evamist in the US and is currently under evaluation by the regulatory authorities in Sweden. Once the product is approved, HRA Pharma will handle its marketing and distribution from its headquarters in Paris, France and from its subsidiaries in Germany, Italy and the UK.
Erin Gainer, CEO of HRA Pharma, said: “We are excited about the opportunities to bring Acrux’s novel transdermal spray to women in Europe and to reinforce our commitment to being the European in-licensing partner of choice in our key therapeutic areas.”